Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD)
- PMID: 23246457
- DOI: 10.1016/j.clinbiochem.2012.12.005
Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD)
Abstract
Aspirin exacerbated respiratory disease (AERD) is a distinct clinical entity characterized by eosinophilic rhinosinusitis, asthma and often nasal polyposis. Exposure to aspirin or other nonsteroid anti-inflammatory drugs (NSAIDs) exacerbates bronchospasms with asthma and rhinitis. Disease progression suggests a skewing towards TH2 type cellular response along with moderate to severe eosinophil and mast cell infiltration. Alterations in upper and lower airway cellular milieu with abnormalities in eicosanoid metabolism and altered eicosanoid receptor expression are the key features underlying AERD pathogenesis. Dysregulation of arachidonic acid (AA) metabolism, notably reduced prostaglandin E2 (PGE2) synthesis compared to their aspirin tolerant counterpart and relatively increased PGD2 production, a TH2/eosinophil chemoattractant are reported in AERD. Underproduced PGE2 is metabolized by overexpression of 15 prostaglandin dehydrogenase (15-PGDH) to inactive products further reducing PGE2 at real time. This relives the inhibitory effect of PGE2 on 5-lipoxygenase (5-LOX) resulting in overproduction of cysteinyl leukotrienes (CysLTs). Diminished formation of CysLT antagonists called lipoxins (LXs) also augments CysLTs responsiveness. Occasional intake of NSAIDs favors even more 5-LOX product formation, further narrowing the bronchoconstrictive bottle neck, resulting in acute asthmatic exacerbations along with increased mucus production. This review focuses on abnormalities in biochemical and molecular mechanisms in eicosanoid biosynthesis, eicosanoid receptor dysregulation and associated polymorphisms with special reference to arachidonic acid metabolism in AERD.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Similar articles
-
An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.Curr Opin Allergy Clin Immunol. 2014 Feb;14(1):1-6. doi: 10.1097/ACI.0000000000000021. Curr Opin Allergy Clin Immunol. 2014. PMID: 24300420 Review.
-
Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.Allergy. 2014 Nov;69(11):1550-9. doi: 10.1111/all.12512. Epub 2014 Sep 12. Allergy. 2014. PMID: 25123806
-
Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2013 Oct;132(4):856-65.e1-3. doi: 10.1016/j.jaci.2013.05.008. Epub 2013 Jun 24. J Allergy Clin Immunol. 2013. PMID: 23806637 Free PMC article.
-
[Physiopathology of aspirin intolerant asthma].Rev Mal Respir. 2012 Feb;29(2):118-27. doi: 10.1016/j.rmr.2011.11.014. Epub 2012 Feb 4. Rev Mal Respir. 2012. PMID: 22405107 Review. French.
-
Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):653-7. doi: 10.1016/j.jaip.2014.09.009. Epub 2014 Nov 6. J Allergy Clin Immunol Pract. 2014. PMID: 25439353 Review.
Cited by
-
Platelets, Not an Insignificant Player in Development of Allergic Asthma.Cells. 2021 Aug 10;10(8):2038. doi: 10.3390/cells10082038. Cells. 2021. PMID: 34440807 Free PMC article. Review.
-
Molecular genetic mechanisms of chronic urticaria.Allergy Asthma Immunol Res. 2014 Jan;6(1):13-21. doi: 10.4168/aair.2014.6.1.13. Epub 2013 Oct 30. Allergy Asthma Immunol Res. 2014. PMID: 24404388 Free PMC article. Review.
-
Low-dose aspirin, maternal cardiometabolic health, and offspring respiratory health 9 to 14 years after delivery: Findings from the EAGeR Follow-up Study.Paediatr Perinat Epidemiol. 2024 Sep;38(7):570-580. doi: 10.1111/ppe.13097. Epub 2024 Jun 17. Paediatr Perinat Epidemiol. 2024. PMID: 38886184
-
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2022 Aug;150(2):415-424. doi: 10.1016/j.jaci.2022.04.007. Epub 2022 Apr 20. J Allergy Clin Immunol. 2022. PMID: 35460728 Free PMC article.
-
Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):38-45. doi: 10.1097/ACI.0000000000000498. Curr Opin Allergy Clin Immunol. 2019. PMID: 30516547 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous